A5010449976- Retinal Diseases and Treatments
- Glaucoma and retinal disorders
- HIV Research and Treatment
- Virus-based gene therapy research
- Herpesvirus Infections and Treatments
- Ocular Surface and Contact Lens
- RNA Interference and Gene Delivery
- Immune Cell Function and Interaction
- Viral Infections and Immunology Research
- CRISPR and Genetic Engineering
- Cytomegalovirus and herpesvirus research
- Retinal and Optic Conditions
- Retinal Development and Disorders
- Proteoglycans and glycosaminoglycans research
- Immunotherapy and Immune Responses
- Neurological Disorders and Treatments
- Genomics and Rare Diseases
- Retinal and Macular Surgery
- vaccines and immunoinformatics approaches
- Animal Virus Infections Studies
Aerie Pharmaceuticals (United States)
2019-2022
Thomas Jefferson University
2015
Jefferson College
2002-2006
New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden improve outcomes relative to currently available agents are needed. Netarsudil, a novel Rho kinase inhibitor approved by the US Food Drug Administration, reduces intraocular pressure (IOP) increasing trabecular outflow. Two phase 3 superiority studies compared fixed-dose combination (FDC) of netarsudil prostaglandin latanoprost with each active component for IOP-lowering efficacy.Pooled...
Intraocular pressure (IOP) reduction is key to controlling primary open angle glaucoma (POAG). Pharmacotherapies for POAG or ocular hypertension (OHT) commonly lower IOP by increasing uveoscleral outflow decreasing aqueous humor production. Netarsudil (Rhopressa), a Rho kinase inhibitor, reduces improving trabecular facility, which reduced in POAG. We investigated the effects of netarsudil on dynamics patients with OHT.Double-masked, randomized, vehicle-controlled, Phase 2 trial.Netarsudil...
Precis: In pooled phase III analyses, once-daily netarsudil 0.02% resulted in intraocular pressure (IOP) reduction that was noninferior to twice-daily timolol 0.5%, with minimal treatment-related serious or systemic adverse events (AEs). Ocular AEs were generally tolerable. Purpose: The purpose of this study assess the efficacy and safety Rho kinase inhibitor patients open-angle glaucoma ocular hypertension. Patients Methods: Pooled analysis data from ROCKET-1 4 studies ( PM ) primary...
A phase 3 trial (MERCURY-1) investigated efficacy and safety of a once-daily, fixed-dose combination (FDC) netarsudil latanoprost, compared with each active component, in reducing elevated intraocular pressure (IOP) patients open-angle glaucoma (OAG) or ocular hypertension (OHT). planned 3-month analysis demonstrated the superiority netarsudil/latanoprost FDC over its individual components at every assessment. Herein, 12-month are reported.Double-masked, randomized, active-controlled,...
Pharmacotherapy to lower intraocular pressure (IOP) is a mainstay of treatment aimed at delaying progression visual field loss in ocular hypertension (OHT) and open-angle glaucoma (OAG), but some topical treatments are less effective controlling IOP night. Peak may be related can occur outside office hours. A phase 2 study was conducted evaluate the IOP-lowering efficacy netarsudil across diurnal nocturnal periods. This randomized, double-masked, single-center, vehicle-controlled, 9-day...
BACKGROUND: A vaccine that elicits durable, powerful anti-HIV immunity remains an elusive goal. In these studies we tested whether multiple treatments with viral vector-delivered HIV envelope antigen (gp120), and without IL-15, could help to approach For this purpose, used recombinant Tag-deleted SV40-derived vectors (rSV40s), since they do not elicit neutralizing antibody responses, so can be given multiply loss of transduction efficiency. METHODS: SV(gp120) carried the coding sequences for...
Purpose: AR-1105 is a novel biodegradable sustained-release dexamethasone implant designed to deliver 6-month durability. This Phase 2 study evaluated two formulations with different release profiles in patients macular edema due retinal vein occlusion. Methods: Patients received single intravitreal injection 340 µ g dexamethasone. In the initial phase, five clinical formulation (CF) 1. randomized 44 were 1:1 CF1 or CF2. The follow-up was 6 months. had vision loss diagnosed ≥9 (central...
Background: Analysis of blood and cells from HIV-positive patients has demonstrated specific cytotoxic T antibodies directed vs. most HIV proteins. These findings suggest that even proteins are predicted to be sub-dominant epitopes, can targeted by the immune system. Thus, just as it is unclear what form(s) an effective prophylactic or therapeutic response against might take, critical antigenic targets also unknown. A promising approach vaccine development use live viral vectors deliver...
Background: The importance of strong anti-lentiviral immune responses for prevention and therapy AIDS, combined with the failure classical immunization techniques to provide either effectively, has led consideration potential utility immunostimulatory cytokines as adjuvants in improving magnitude rapidity such responses. Delivery cytokines, concert antigen question, might be facilitated by using recombinant Tag-deleted SV40 vectors (rSV40s). These do not elicit detectable neutralizing...